DRMA · All filings · Read this filing
What changed 10-Q
Item 5. Other Information
2024-05-15 compared with 2023-11-09 · 1 added, 3 removed, 21 unchanged (16% of the section changed)
OTHER INFORMATION
−Removed: Second Amendment to the Dermata Therapeutics, Inc.
−Removed: 2021 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 3, 2023).
+Added: (c) During the fiscal quarter ended March 31, 2024, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(c) of Regulation S-K.
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
13 unchanged sentences
Dermata Therapeutics, Inc.
−Removed: November 9, 2023
/s/ Gerald T.
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.